Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15601289 | 0.95 | KEAP1 (0.46) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL18838507 | 0.86 | KEAP1 (0.49) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL18838508 | 0.80 | NAMPT (0.46) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL18838380 | 0.80 | NAMPT (0.46) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL18838379 | 0.79 | STS (0.51) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL15577383 | 0.77 | KEAP1 (0.38) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL25390723 | 0.76 | STS (0.53) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL519045 | 0.76 | STS (0.53) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL34467906 | 0.76 | KEAP1 (0.49) | KEAP1NFE2L2GPR119STSKDM1A | |
| SCHEMBL16914194 | 0.75 | ALDH1A1 (0.51) | GPR119STSLMNATP53NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895488-B1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| EP-2895488-A1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | Trius Therapeutics, Inc. (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043272-A1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | TRIUS THERAPEUTICS INC. (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | KEAP1 2946/4885NFE2L2 3479/4885GPR119 4529/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | KEAP1 2946/4885NFE2L2 3479/4885GPR119 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.